Johnson & Johnson (NYSE:JNJ) is significantly expanding its biotechnology portfolio with two major deals, securing a $1 billion acquisition of Firefly Bio Inc. and forging a strategic partnership with Sail Biomedicines that includes an option to purchase the latter for $2.58 billion.
Targeting Solid Tumors With Firefly Bio
The healthcare giant successfully finalized its $1 billion cash purchase of Firefly Bio, earlier announced in June. The strategic move integrates the proprietary Firelink degrader antibody conjugate platform into the company’s oncology pipeline.
The technology addresses a major unmet medical need by targeting challenging solid tumors, including KRAS-driven cancers.
It functions by delivering highly selective protein degraders straight to cancer cells while protecting healthy tissue, overcoming a primary limitation of existing treatments.
The buyout will trigger an in-process research and development charge of approximately $1 billion during the third quarter of 2026.
Consequently, the transaction is projected to reduce adjusted earnings per share by roughly $0.46 in 2026 and $0.08 in 2027.
Pioneering CAR-T Therapies With Sail Biomedicines
The pharmaceutical leader on Thursday revealed a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated conditions.
Building on its established expertise in immunology and oncology, this partnership aims to advance curative treatment approaches.
Unlike conventional cell treatments, Sail’s platform is designed to reprogram a patient’s immune cells directly inside the body. This innovative approach seeks to reset the immune system and deliver durable disease control.
The agreement involves $785 million in upfront payments, which includes a $465 million equity stake, alongside $140 million tied to specific development milestones.
Furthermore, the firm secured an exclusive right to acquire Sail for an additional $2.58 billion.
If executed, this buyout would dilute adjusted operational earnings per share by about $0.18 in 2026 and $1.28 in 2027.
JNJ Price Action: Johnson & Johnson shares were down 3.63% at $255.88 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock